Vivos Therapeutics (VVOS) Research & Development (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of Research & Development data on file, last reported at $249000.0 in Q1 2026.

• On a quarterly basis, Research & Development fell 30.45% year-over-year to $249000.0 in Q1 2026; TTM through Mar 2026 was $1.3 million, a 9.89% decrease from a year earlier, with the FY2025 full-year figure at $1.4 million, down 19.12% from the prior year.
• Research & Development for Q1 2026 stood at $249000.0, down from $382000.0 in the prior quarter.
• Over the last five years, Research & Development for VVOS reached as high as $1.7 million in Q2 2022 and fell as low as $249000.0 in Q1 2026.
• Historically, Research & Development has averaged $633235.3 across 5 years, with a median of $590000.0 in 2023.
• Across the five-year window, Research & Development rose 21.53% in 2022 and slumped 65.27% in 2023, its largest moves.
• Year by year, Research & Development stood at $1.4 million in 2022, then tumbled by 55.28% to $606000.0 in 2023, then plunged by 32.01% to $412000.0 in 2024, then dropped by 7.28% to $382000.0 in 2025, then plunged by 34.82% to $249000.0 in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $249000.0 in Q1 2026, $382000.0 in Q4 2025, and $403000.0 in Q3 2025.